Lactobio conclude the first clinical trial on dry and atopic skin

Lactobio conclude the first clinical trial on dry and atopic skin

Lactobio’s probiotic skincare substantially improves dry and atopic skin, a new clinical trial has concluded.

Numerous genetic and environmental factors contribute to skin problems such as atopic and dry skin, but it is well-established that the skin microbiome (ecosystem of microorganisms) influence the health and balance of the skin.

Using Lactobio’s probiotic skincare over a 14-day period, redness, sores, and abrasions were substantially reduced in 67% of the participants*, while dryness and itching were substantially reduced in 96%**.

“Based on our lab results and the recently concluded study, we are confident that our probiotic solutions are the future of skincare. Taking care of your skin microbiome means taking care of your skin. With our products, customers now have an easy and accessible way of doing that,” says Charlotte Vedel, PhD and COO of Lactobio.

*Eczema Area Severity Index (EASI index). **Visual Analoque Scale (VAS score). Clinical cosmetics study including 20 participants.

Targeted probiotic bacterial strains

Typically, probiotic strains are not selected for a targeted function and most of the commercial strains available are often older isolates. In Lactobio, we have isolated more than a thousand strains and screened for their specific functionalities. 

Lactiplantibacillus plantarum LB244R® (formerly Lactobacillus plantarum) was isolated from fermented kale and selected for its ability to out-balance Staphylococcus aureus and for its production of desired metabolites such as peptides, bacteriocins, amino acids, vitamins, and free fatty acids – all of which create a healthier skin environment.

The probiotic bacteria also strengthen the immune system by promoting the production of defensins and by strengthening the barrier function by stabilizing the tight junctions of the skin.

LB244R® is a registered trademark of Lacobio A/S